/BMRA
BMRA Stock - Biomerica, Inc.
Healthcare|Medical - DevicesNASDAQ
$2.31-1.70%
$0.04 (-1.70%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.54
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BMRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.29 – $2.33
TARGET (TP)$2.66
STOP LOSS$2.13
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.06
52W High$10.16
52W Low$2.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.31M | $5.42M | $5.34M | $18.87M | $7.20M |
| Gross Profit | $498,000 | $611,000 | $446,000 | $2.98M | $366,285 |
| Gross Margin | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% |
| Operating Income | $-5,137,000 | $-6,367,000 | $-7,223,000 | $-4,533,964 | $-7,499,693 |
| Net Income | $-4,973,000 | $-5,978,000 | $-7,140,000 | $-4,531,044 | $-7,446,254 |
| Net Margin | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% |
| EPS | $-2.16 | $-0.36 | $-0.50 | $-0.36 | $-0.54 |
Company Overview
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BMRABeat Rate
11%
Last 9 quarters
Avg Surprise
-199.6%
EPS vs Estimate
Beats / Misses
1/7
1 met exactly
Latest EPS
$0.00
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q1 2026 | Jan 13, 2026 | — | — | — | — |
Q4 2025 | Oct 14, 2025 | — | $0.00 | — | — |
Q2 2025 | Apr 14, 2025 | — | $-0.48 | — | — |
Q1 2025 | Jan 14, 2025 | — | $-0.06 | — | — |
Q4 2024 | Oct 15, 2024 | — | $-0.08 | — | — |
Q3 2024 | Aug 28, 2024 | — | $-0.09 | — | — |
Q2 2024 | Apr 12, 2024 | — | $-0.11 | — | — |
Q1 2024 | Jan 16, 2024 | — | $-0.09 | — | — |
Q4 2023 | Oct 12, 2023 | — | $-0.07 | — | — |
Q3 2023 | Aug 25, 2023 | $0.04 | $-0.10 | -350.0% | ✗ MISS |
Q2 2023 | Apr 14, 2023 | $0.02 | $-0.12 | -700.0% | ✗ MISS |
Q1 2023 | Jan 13, 2023 | — | $-0.12 | — | — |
Q4 2022 | Oct 13, 2022 | $-0.02 | $-0.16 | -700.0% | ✗ MISS |
Q3 2022 | Aug 29, 2022 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q2 2022 | Apr 14, 2022 | $-0.10 | $-0.01 | +90.0% | ✓ BEAT |
Q1 2022 | Jan 12, 2022 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q4 2021 | Oct 14, 2021 | $-0.12 | $-0.12 | 0.0% | = MET |
Q3 2021 | Aug 27, 2021 | $-0.10 | $-0.12 | -20.0% | ✗ MISS |
Q2 2021 | Apr 14, 2021 | $-0.08 | $-0.15 | -87.5% | ✗ MISS |
Latest News
Biomerica Highlights Clinical Trial Showing inFoods IBS Test Significantly Reduces Symptoms Through Guided Dietary Therapy In The Fall 2025 Issue Of Biotherapeutics Quarterly, A Henry Schein Publication
📈 PositiveBenzinga•Nov 25, 2025, 01:22 PM•Also:
Biomerica Expands CDMO Services To Meet Rising Demand From Diagnostic And Biotech Companies
📈 PositiveBenzinga•Nov 6, 2025, 01:38 PM
Biomerica Enters Marketing Partnership With Henry Schein To Promote Biomerica's Infoods Irritable Bowel Syndrome Test Across The United States, Excluding New York State
📈 PositiveBenzinga•Oct 16, 2025, 12:22 PM•Also:
Biomerica Partners With Henry Schein To Market Non-Drug IBS Test Nationwide
📈 PositiveBenzinga•Oct 16, 2025, 12:21 PM•Also:
Biomerica Q1 Sales $1.380M Down From $1.807M YoY
📉 NegativeBenzinga•Oct 14, 2025, 10:01 PM
Biomerica Launches AI-Powered Tool To Help IBS Patients Manage Symptoms And Avoid Trigger Foods Identified By inFoods Testing
📈 PositiveBenzinga•Sep 9, 2025, 12:09 PM
BMRA stock has given up its prior gain. Biomerica shares were trading higher after the UAE Ministry of Health and Prevention approved the company's Fortel Kidney Test for home use.
➖ NeutralBenzinga•Sep 3, 2025, 02:16 PM
Biomerica shares are trading higher after the UAE Ministry of Health and Prevention approved the company's Fortel Kidney Test for home use.
📈 PositiveBenzinga•Sep 3, 2025, 12:20 PM
Biomerica's 10-Minute Fortel Kidney Test Approved For Home Use In UAE To Aid Early Detection In Diabetic And Hypertensive Patients
📈 PositiveBenzinga•Sep 3, 2025, 12:20 PM
Biomerica Q4 EPS $(0.69) Up From $(0.72) YoY, Sales $749.000K Down From $1.118M YoY
➖ NeutralBenzinga•Aug 29, 2025, 09:35 PM
Biomerica stock plummets on 1-for-8 reverse stock split
📉 NegativeSeeking Alpha•Apr 16, 2025, 01:14 PM
Frequently Asked Questions about BMRA
What is BMRA's current stock price?
Biomerica, Inc. (BMRA) is currently trading at $2.31 per share. The stock has moved -1.70% today.
What is the analyst price target for BMRA?
No analyst price targets are currently available for this stock.
What sector is Biomerica, Inc. in?
Biomerica, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is BMRA's market cap?
Biomerica, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BMRA pay dividends?
No, Biomerica, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALZN
Alzamend Neuro, Inc.
$2.11
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
HSCS
HeartSciences Inc.
$2.36
Mkt Cap: $0.0B
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$1.02
Mkt Cap: $0.0B
LFWD
Lifeward Ltd.
$0.65
Mkt Cap: $0.0B
LUCY
Innovative Eyewear, Inc.
$1.38
Mkt Cap: $0.0B
PAVM
PAVmed Inc.
$0.31
Mkt Cap: $0.0B
PTHL
Pheton Holdings Ltd Class A Ordinary Shares
$0.50
Mkt Cap: $0.0B
SINT
Sintx Technologies, Inc.
$3.61
Mkt Cap: $0.0B
SSKN
STRATA Skin Sciences, Inc.
$1.19
Mkt Cap: $0.0B
Explore stocks similar to BMRA for comparison